WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of SCICLONE PHARMA (SCLN)

Name SCICLONE PHARMA
Year low 3.30
Year High 6.88
Symbol SCLN
Last trade 5.10
Percentage change 0.59
Volume 191,454
Media Volume (3m) 209,627
PE Ratio 14.04
EPS 0.361
Market Cap 298
Media fatt 122
Trend fatt trend fatt graph for SCICLONE PHARMA
Media net income 21
Trend net income trend net income for SCICLONE PHARMA
P / E P / E graph for SCICLONE PHARMA - 13 points 13
EPS EPS graph for SCICLONE PHARMA - 8 points 8
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for SCICLONE PHARMA - 4 points 4
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for SCICLONE PHARMA - 7 points 7
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for SCICLONE PHARMA - 12 points 12
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for SCICLONE PHARMA - 11 points 11
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for SCICLONE PHARMA - 5 points 5
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for SCICLONE PHARMA - 8 points 8
NET INC1/NET INC3 net inc1/net inc3 graph for SCICLONE PHARMA - 10 points 10
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for SCICLONE PHARMA - 8 points 8
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for SCICLONE PHARMA - 0 points 0
. . graph for SCICLONE PHARMA - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for SCICLONE PHARMA - 2 points 2
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for SCICLONE PHARMA - 2 points 2
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for SCICLONE PHARMA - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for SCICLONE PHARMA - 0 points 0
. . graph for SCICLONE PHARMA - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for SCICLONE PHARMA - 0 points 0
SINTESE 90

GRAPHS

max price logarithm graph for SCICLONE PHARMA based on no conditions max volume linear graph for SCICLONE PHARMA based on no conditions

News

SciClone Pharmaceuticals to Present at Two Investor Conferences in September (Sep 01 - reuters) SciClone Reports Financial Results for the Second Quarter of 2011 (Aug 09 - reuters) SciClone Pharmaceuticals to Report Second Quarter 2011 Financial Results on August 9 (Jul 29 - reuters) » More SCLN.O Market Views (Jul 15 - reuters) What the Market Wants: A Flight to Risk (Jun 28 - reuters) SciClone Presents New Preclinical Data Highlighting Potential Role of SCV-07 in Cancer Treatment at 2011 ASCO Annual (Jun 04 - reuters) SciClone Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference (Jun 02 - reuters) SciClone: Novamed Acquisition Helps, But Questions Remain (May 20 - reuters) SciClone to Present New Preclinical Data on SCV-07 at 2011 ASCO Annual Meeting (May 19 - reuters) SciClone Pharmaceuticals Provides First Quarter Results and Updates 2011 Guidance (May 10 - reuters) » More SCLN.MW Market Views (May 07 - reuters) SciClone Pharmaceuticals to Report First Quarter 2011 Results on May 10 (Apr 29 - reuters) SciClone Acquires NovaMed Pharmaceuticals Further Establishing It as a Leading China-Focused Specialty Pharmaceutical (Apr 19 - reuters) 19 High Growth Micro Cap Stocks Under $10 (Apr 15 - reuters) SciClone Pharmaceuticals Provides Fourth Quarter and Year End 2010 Results and 2011 Guidance (Apr 15 - reuters) SciClone Pharmaceuticals to Provide Financial Update on April 1 (Apr 15 - reuters) SciClone Reports Preliminary Financial Results for the Fourth Quarter and Year End 2010 (Apr 15 - reuters) SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results for 2010 on March 16 (Apr 15 - reuters) SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference (Apr 15 - reuters) SciClone Initiates Phase 2b Study of SCV-O7 for Treatment of Oral Mucositis (Apr 15 - reuters) SciClone Announces Topline Results From Phase 2b Clinical Trial of SCV-07 for Treatment of Chronic Hepatitis C (Apr 15 - reuters) SciClone Pharmaceuticals to Present at Two Investor Conferences in November (Apr 15 - reuters) 10 Pharma Stocks With 100% Buy Ratings (Apr 15 - reuters) The Fool Looks Ahead (Apr 15 - reuters) 5 Stocks That Might Not Be Trading Under $5 Much Longer (Apr 15 - reuters) » More SCLN.O Market Views (Apr 15 - reuters) SciClone Pharmaceuticals to Present at Two Investor Conferences in March (Apr 15 - reuters) CORRECTED - UPDATE 1-SciClone says internal probe to delay annual report (Mar 17 - reuters) UPDATE 1-SciClone Pharma Q3 EPS beats, raises FY profit view (Jan 28 - reuters) Bribery investigations spark shareholder suits (Jan 28 - reuters) STOCKS NEWS UK-Velosi falls on results, margin outlook (Jan 28 - reuters) STOCKS NEWS EUROPE-Biocompatibles up on bid approach (Jan 28 - reuters) UPDATE 1-SciClone shares plunge on SEC, DoJ probe (Jan 28 - reuters) UPDATE 1-SciClone to stop development of HCV drug, shares fall (Jan 28 - reuters) UPDATE 1-SciClone says SEC starts formal probe, shares fall (Jan 28 - reuters) HEADLINE STOCKS-U.S. small/midcap stocks to watch on Aug 10 (Jan 28 - reuters) SciClone shares plunge on SEC probe (Jan 28 - reuters) UPDATE 1-SciClone to stop development of HCV drug, shares fall (Dec 15 - reuters) Kahn Swick & Foti, LLC Announce Continuing Investigation into SciClone Pharmaceuticals, Inc. – Firm Appointed Co-lead Counsel in Securities Class Action – SCLN (Nov 29 - businesswire) Bribery investigations spark shareholder suits (Nov 27 - reuters) STOCKS NEWS UK-Velosi falls on results, margin outlook (Nov 27 - reuters) STOCKS NEWS EUROPE-Biocompatibles up on bid approach (Nov 27 - reuters) UPDATE 1-SciClone shares plunge on SEC, DoJ probe (Nov 27 - reuters) SciClone shares plunge on SEC probe (Nov 27 - reuters) UPDATE 1-SciClone says SEC starts formal probe, shares fall (Nov 27 - reuters) UPDATE 1-SciClone Pharma Q3 EPS beats, raises FY profit view (Nov 27 - reuters) UPDATE 1-SciClone Q1 profit tops Street, backs FY10 outlook (Nov 27 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY